Loading clinical trials...

Gene Therapy for Fanconi Anemia | Clinical Trials | Clareo Health

TERMINATEDPHASE1

Gene Therapy for Fanconi Anemia

Gene Transfer for Patients With Fanconi Anemia Complementation Group A (FANCA)

NCT01331018•Fred Hutchinson Cancer Center

Summary

This clinical trial will access the toxicity and efficacy of infusion of gene modified cells for patients with Fanconi anemia (FA). Infusion of autologous patient blood stem cells that have been corrected in the laboratory by introduction of the normal gene may improve blood counts in patients with FA.

Detailed Description

OUTLINE: STEM CELL MOBILIZATION FOR CELL COLLECTION: Patients receive filgrastim subcutaneously (SC) twice daily (BID) for up to 6 days (on days 1-6 of mobilization). Patients receive plerixafor SC once daily (QD) on days 4-6 of mobilization. Peripheral blood stem cell (PBSC) count will be checked daily starting on day 4 of mobilization. Patients who have a PBSC count of \>= 5 CD34+ cells/mcL will undergo up to 2 apheresis collections on consecutive days. BONE MARROW HARVEST FOR CELL COLLECTION: Patients with inadequate PBSC counts undergo bone marrow harvest for collection of stem/progenitor cells. REINFUSION: Patients receive methylprednisolone intravenously (IV) or prednisone orally (PO) on days -1 to 7 followed by a rapid taper over approximately 1 week and undergo reinfusion of genetically modified hematopoietic stem/progenitor cells on day 0. After completion of study treatment, patients are followed up periodically for 15 years.

Eligibility

Age

4 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•FA demonstrated by a positive test for increased sensitivity to chromosomal breakage with mitomycin C or diepoxybutane performed by a Clinical Laboratory Improvement Amendments (CLIA) or College of American Pathologists (CAP) approved laboratory
•FA complementation group A as determined by somatic cell hybrids, molecular characterization, western blot analysis, acquisition of mitomycin C resistance after in vitro lentiviral transduction with a vector bearing the complementary deoxyribonucleic acid (cDNA) for Fanconi complementation group A, or other clinically certified method of complementation group analysis
•Bone marrow analysis demonstrating normal cytogenetics, and no more than 5% of cells with a single clonal abnormality by fluorescence in situ hybridization (FISH) for myelodysplastic syndrome (MDS) panel within 3 months of stem cell collection
•Signed informed consent by the patient or legally authorized representative
•Absolute neutrophil count \>= 0.5 x 10\^9/L
•Hemoglobin \>= 8 g/dL
•Platelet count \>= 20 x 10\^9/L and able to achieve a platelet count of \>= 50 x 10\^9/L with transfusion support
•Adequate hepatic function with aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 5 x upper limit of normal (ULN)
•Adequate renal function with creatinine (Cre) =\< 1.5; if greater, then glomerular filtration rate (GFR) \> 60 mL/min/1.73 m\^2 as calculated by the Modification of Diet in Renal Disease equation
•Adequate pulmonary function with corrected diffusion capacity of carbon monoxide (DLCO) \> 50% in those for whom this study can be performed
+1 more criteria

Exclusion Criteria

•Non-hematopoietic malignancy where the expected survival is less than 2 years
•Myelodysplastic syndrome as defined by World Health Organization (WHO) criteria
•Acute myeloid leukemia as defined by WHO criteria
•Pregnancy or lactation; females of childbearing potential and males who are admitted to the study will be advised that the study procedures and study drugs may be teratogenic, and they will be required to take adequate measures to prevent conception for the duration of the study
•Concurrent enrollment in any other study using an investigational drug
•Physical or emotional status that would prevent informed consent, protocol compliance, or adequate follow-up
•Patients for whom an human leukocyte antigen (HLA) matched sibling donor bone marrow transplant is being actively pursued will not be eligible for study until it is determined that no sibling donor is available or that a stem cell transplant is not feasible during the time the patient might be on study
•* No patient will be included in this study as an alternative to a clinically indicated HLA matched sibling donor stem cell transplant
•* If an HLA matched sibling donor is identified, but stem cell or marrow collection is not feasible (e.g., donor is in utero, is a newborn from whom cord blood was not collected, or is unable to undergo a donation procedure because of ill health), a patient may be included in the study at the discretion of the investigators
•Significant associated diseases including documented human immunodeficiency virus (HIV) infection, uncontrolled hypertension (diastolic blood pressures \> 95%ile for age), unstable angina, congestive heart failure (\> New York \[NY\] class II), poorly controlled diabetes (hemoglobin A1c \[Hgb A1c\] \> 7%), coronary angioplasty within 6 months, myocardial infarction within the last 6 months, or uncontrolled atrial or ventricular cardiac arrhythmia, abnormal coagulation, persistent abnormal urinalysis reflecting intrinsic renal disease
+1 more criteria

Locations (1)

Fred Hutch/University of Washington Cancer Consortium

Seattle, Washington, United States

Key Dates

Start Date

February 22, 2012

Primary Completion Date

February 15, 2024

Completion Date

February 15, 2024

Last Updated

May 17, 2024

Enrollment

ACTUAL participants

Conditions

Fanconi Anemia

Interventions

Bone Marrow Aspiration

PROCEDURE

Filgrastim

BIOLOGICAL

Genetically Engineered Hematopoietic Stem Progenitor Cells

BIOLOGICAL

Laboratory Biomarker Analysis

OTHER

Leukapheresis

PROCEDURE

Methylprednisolone

DRUG

Plerixafor

DRUG

Prednisone

DRUG

Familial Investigations of Childhood Cancer Predisposition

NCT03050268

Acute LeukemiaAdenomatous Polyposis+44 more

View study

RECRUITINGPHASE2

HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

NCT02143830

Fanconi AnemiaSevere Marrow Failure+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 17, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Gene Therapy for Fanconi Anemia

Inclusion Criteria

Exclusion Criteria

Familial Investigations of Childhood Cancer Predisposition

HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

Quercetin Chemoprevention for Squamous Cell Carcinoma in Patients With Fanconi Anemia

Prenatal Transplantation for Fetuses With Fanconi Anemia

Expanded Access to CD34+ Selection Utilizing Miltenyi CliniMACS Prodigy® for Patients Receiving Peripheral Blood Stem Cell Transplantations and Stem Cell Boosts

Safety and Efficacy of Metformin for Treatment of Cytopenia in Children and Adolescents With Fanconi Anemia